HbA1c Measurements Predict Heart Disease in Diabetics
|
By LabMedica International staff writers Posted on 10 Aug 2011 |
|
The measurement of hemoglobin 1Ac (Hb1Ac) in patients with diabetes improves the prediction of cardiovascular disease (CVD) events occurring.
The glycosalated HbA1c test reflects the average blood glucose level over the previous 8 to 13 weeks and is generally viewed as an indicator on how well the patient is managing or controlling their diabetes.
A team of scientists at Brigham and Women's Hospital (Boston, MA, USA) set out to determine how useful monitoring HbA1c levels might be in predicting cardiovascular events. They gathered data from 24,674 females, of whom 685 had had diabetes at baseline, while out of 11,280 males 563 had diabetes at baseline. Baseline blood samples were evaluated for HbA1c, C-reactive protein, and cholesterol levels. The females were followed up for new CVD incidents for an average of 10.2 years, and the males for 11.8 years.
The results of the study showed that within the female cohort, there were 125 cardiovascular events out of 685 diabetic participants, compared to 665 out of 24,674 without diabetes. For the male diabetic cohort there were 170 cardiovascular events out of 563 participants, compared to 1,382 out of 11,280 without diabetes. The scientists noted that including HbA1c modeling for CVD improved CVD prediction compared to the general prediction of all high-risk diabetes participants. This was especially the case among females. The risk modeling showed that 71.9% of women with diabetes in this study had a less than 20% risk of CVD over a ten-year period, compared to just 24.5% of their male counterparts.
The study concluded that in these large population-based cohorts of both men and women, presence of diabetes alone did not confer a 10-year risk of CVD higher than 20%, and measurement of HbA1c level in diabetic subjects improved risk prediction compared with classification as cardiovascular risk equivalent. The study was published on July 25, 2011, in the Archives of Internal Medicine.
Related Links:
Brigham and Women's Hospital
The glycosalated HbA1c test reflects the average blood glucose level over the previous 8 to 13 weeks and is generally viewed as an indicator on how well the patient is managing or controlling their diabetes.
A team of scientists at Brigham and Women's Hospital (Boston, MA, USA) set out to determine how useful monitoring HbA1c levels might be in predicting cardiovascular events. They gathered data from 24,674 females, of whom 685 had had diabetes at baseline, while out of 11,280 males 563 had diabetes at baseline. Baseline blood samples were evaluated for HbA1c, C-reactive protein, and cholesterol levels. The females were followed up for new CVD incidents for an average of 10.2 years, and the males for 11.8 years.
The results of the study showed that within the female cohort, there were 125 cardiovascular events out of 685 diabetic participants, compared to 665 out of 24,674 without diabetes. For the male diabetic cohort there were 170 cardiovascular events out of 563 participants, compared to 1,382 out of 11,280 without diabetes. The scientists noted that including HbA1c modeling for CVD improved CVD prediction compared to the general prediction of all high-risk diabetes participants. This was especially the case among females. The risk modeling showed that 71.9% of women with diabetes in this study had a less than 20% risk of CVD over a ten-year period, compared to just 24.5% of their male counterparts.
The study concluded that in these large population-based cohorts of both men and women, presence of diabetes alone did not confer a 10-year risk of CVD higher than 20%, and measurement of HbA1c level in diabetic subjects improved risk prediction compared with classification as cardiovascular risk equivalent. The study was published on July 25, 2011, in the Archives of Internal Medicine.
Related Links:
Brigham and Women's Hospital
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Coagulation Analyzer
CS-2400
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
